Previous close | 7.40 |
Open | 7.50 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 7.35 - 7.35 |
52-week range | 5.25 - 22.20 |
Volume | |
Avg. volume | 1,459 |
Market cap | 13.976M |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.05 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | 0.60 (8.16%) |
Ex-dividend date | 19 Jan 2024 |
1y target est | N/A |
BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 4,968,945 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 4,968,945 shares of common stock and short
Cyclacel Pharmaceuticals, Inc. ( NASDAQ:CYCC ) is possibly approaching a major achievement in its business, so we would...
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data fr